DNB Carnegie analyst Erik Hultgard upgraded Camurus (CAMRF) to Buy from Hold with an SEK 800 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMRF:
- Camurus’ Oczyesa Gains EU Approval for Acromegaly Treatment
- Camurus Expands Share Count to Support Employee Incentive Program
- Camurus’ POSITANO Study Shows Promising Results for PLD Treatment
- Camurus, Lilly enter collaboration pact for long-acting FluidCrystal incretins
- Camurus Partners with Eli Lilly for Long-Acting Incretin Therapies